ELGIA THERAPEUTICS, INC.
Selective caspase-6 inhibitors for Alzheimer's disease treatment
- Sector
- Biotech
- Headquarters
- SAN DIEGO, CA
- Founded
- 2019
- Latest Form D
- $2.3M, May 2020
- Total capital
- $2.6M
- Federal grants
- $288K
- 2 awards · 2023–2024
- Rank in peer group#113 of 392
- Private capital raised
- $2.3M
- 1 Form D · last May 2020
- 78 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 2 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Optimizing brain penetrance of caspase-6 inhibitors to treat neurodegenerative diseases$107K
- Federal grantHealth and Human S · Phase I · Optimizing brain penetrance of caspase-6 inhibitors to treat neurodegenerative diseases$180K
- Private capital raisedForm D · SEC · 1st filing$2.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#113 · top 29%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alan SaltielExecutive Officer, DirectorNamed in SEC Form D filings
- Ariel FeldsteinExecutive Officer, DirectorNamed in SEC Form D filings
- Brian HubbardDirectorNamed in SEC Form D filings
- Thomas CollExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 2- PendingInhibitors Of PROCASPASE-6 Activation And Uses ThereofUSPTOApplication 19138034
- PendingInhibitors Of PROCASPASE-6 Activation And Uses ThereofUSPTOApplication 63432560
Related companies, and why
- Hummingbird Nano, Inc.Similar federal contract value in Biotech · null in contracts
- Upstream BioSimilar federal contract value in Biotech · null in contracts
- BIOMEDIT LLCSimilar federal contract value in Biotech · null in contracts
- WHITE ROCK THERAPEUTICSSimilar federal contract value in Biotech · null in contracts
- Neogene TherapeuticsSimilar federal contract value in Biotech · null in contracts
- VBI VACCINES INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .